Download PDF
Aktuelle Dermatologie 2002; 28(8/9): 297-301
DOI: 10.1055/s-2002-33964
Tumormarker
© Georg Thieme Verlag Stuttgart · New York

Bestimmung der Tumormarker S-100B und MIA im Blut von Melanompatienten

Determination of Tumor Markers S-100B and MIA in the Blood of Melanoma PatientsA.  Hauschild1 , S.  Eiling1
  • 1Klinik für Dermatologie, Venerologie und Allergologie, Christian-Albrechts-Universität zu Kiel
Further Information

Publication History

Publication Date:
10 September 2002 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Bei den meisten soliden Tumoren können mehr oder weniger spezifische tumorassoziierte Moleküle im Blut nachgewiesen werden. Beim malignen Melanom stehen mit den kommerziell erhältlichen Nachweisverfahren zur Quantifizierung von Protein S-100B (Sangtec100-LIA) und „melanoma-inhibitory activity” (MIA-ELISA) gleich zwei Testkits zur Verfügung. Vergleichende Untersuchungen haben gezeigt, dass bei einer Spezifität von 95 % etwa 70 bis 90 % aller Patienten mit fernmetastasiertem Melanom durch erhöhte Serumwerte von S-100B bzw. MIA auffallen. Beide Tumormarker-Werte im Blut korrelieren stadienabhängig sehr gut mit der Prognose von Melanompatienten, so dass ein effektives Therapiemonitoring möglich wird. Durch S-100B- und MIA-Bestimmungen können jedoch ganz offensichtlich keine okkulten Mikrometastasen entdeckt werden, so dass ihre Verwendung nur bei Patienten mit erhöhtem Metastasierungsrisiko sinnvoll erscheint.

Abstract

In the majority of solid neoplasia a detection of tumor-associated molecules in blood is possible. In malignant melanoma, two commercially available test systems to quantify melanoma-associated proteins S-100B (Sangtec 100-LIA), and melanoma inhibitory activity (MIA-ELISA) can be used in routine. Comparative studies revealed that at a specificity of 95 % about 70 to 90 % of advanced metastatic melanoma patients will demonstrate elevated S-100B or MIA serum concentrations. Both markers show a stage-dependent correlation of serum values with prognosis of the patients. Thus, therapy monitoring using these melanoma markers seems to be attractive. Unfortunately, detection of occult micrometastasis is obviously unrealistic. The use of S-100 and MIA detection in serum should be limited to patients with a substantial risk of metastasis.

Literatur

  • 1 Bonfrer J M, Korse C M, Nieweg O E, Rankin E M. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma.  Br J Cancer. 1998;  77 2210-2214
    PubMedGoogle Scholar
  • 2 Bosserhoff A K, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.  Cancer Res. 1997;  57 3149-3153
    PubMedGoogle Scholar
  • 3 Bosserhoff A K, Golob M, Buettner R, Landthaler M, Hein R. MIA (Melanoma inhibitory activity).  Hautarzt. 1998;  49 762-769
    CrossrefPubMedGoogle Scholar
  • 4 Bosserhoff A K, Hauschild A, Hein R, Schadendorf D, Stockfleth E, Bogenrieder T, Landthaler M, Buettner R, Stolz W. Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter study.  J Invest Dermatol. 2000;  114 395-396
    PubMedGoogle Scholar
  • 5 Chu T M. Prostate-specific antigen. In: Sell S (Ed) Serological Cancer Markers. Totowa; Humana Press 1992: 99-115
    Google Scholar
  • 6 Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H. S100-β, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.  J Clin Oncol. 1999;  17 1891-1896
    PubMedGoogle Scholar
  • 7 Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Comparison of S-100 protein and MIA protein as serum marker for malignant melanoma.  Anticancer Res. 2000;  20 2203-2207
    PubMedGoogle Scholar
  • 8 Djukanovic D, Hofmann U, Sucker A, Schadendorf D. Melanoma tumor markers S100B and MIA: evaluation of stability in serum and blood upon storage an processing.  Br J Dermatol. 2001;  145 1-3
    PubMedGoogle Scholar
  • 9 Donato R. Functional roles of S100 proteins, calcium-binding proteins of EF-hand type.  Biochim Biophys Acta. 1999;  1450 191-231
    CrossrefPubMedGoogle Scholar
  • 10 Dummer R, Bosch U, Panizzon R, Bloch P H, Burg G. Task force ‘Skin Cancer'. Swiss National Program against Cancer. Swiss Cancer League. Swiss guidelines for the treatment and follow-up of cutaneous melanoma.  Dermatology. 2001;  203 75-80
    CrossrefPubMedGoogle Scholar
  • 11 Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, Lejeune F. On the release and half-life of S 100B protein in the peripheral blood of melanoma patients.  Int J Cancer. 2001;  94 586-590
    CrossrefPubMedGoogle Scholar
  • 12 Gläser R. Tumormarker des malignen Melanoms. In: Garbe C, Dummer R, Kaufmann R, Tilgen W (Hrsg) Dermatologische Onkologie. Berlin; Springer 1997: 324-329
    Google Scholar
  • 13 Guo H B, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D. Clinical significance of serum S100 in metastatic malignant melanoma.  Eur J Cancer. 1995;  31 924-928
    CrossrefPubMedGoogle Scholar
  • 14 Hauschild A. The use of serological tumor markers for malignant melanoma.  Onkologie. 1997;  20 462-465
    PubMedGoogle Scholar
  • 15 Hauschild A, Engel G, Brenner W, Gläser R, Monig H, Henze E, Christophers E. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.  Oncology. 1999;  566 338-344
    PubMedGoogle Scholar
  • 16 Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, Christophers E. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.  Br J Dermatol. 1999;  144 1065-1071
    PubMedGoogle Scholar
  • 17 Henze G, Dummer R, Joller-Jemelka H I, Böni R, Burg G. Serum S100 - a marker for disease monitoring in metastatic melanoma.  Dermatology. 1997;  194 208-212
    PubMedGoogle Scholar
  • 18 Hossfeld D K. Tumor marker terrorism. Educational Book; 21. Congress European Society of Medical Oncology (ESMO); 1. - 5. 11. 1996. Wien; 1996: 191-192
    Google Scholar
  • 19 Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R, Bosserhoff A. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.  Tumour Biol. 2001;  22 54-58
    PubMedGoogle Scholar
  • 20 Klapdor R. Überlegungen zu einem sinnvollen Einsatz von Tumormarkern.  Onkologe. 1995;  1 627-633
    PubMedGoogle Scholar
  • 21 Krähn G, Kaskel P, Sander S, Waizenhofer P F, Wortmann S, Leiter U, Peter R U. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occured melanoma metastases compared with MIA, albumin and lactate dehydrogenase.  Anticancer Res. 2001;  21 1311-1316
    PubMedGoogle Scholar
  • 22 Miliotes G, Lyman G H, Cruse C W, Puleo C, Albertini J, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, VanVoorhis N, Reintgen D. Evaluation of new putative tumor markers for melanoma.  Ann Surg Oncol. 1996;  3 558-563
    PubMedGoogle Scholar
  • 23 Moore B W. A soluble protein characteristic of the nervous system.  Biochem Biophys Res Commun. 1965;  19 739-744
    CrossrefPubMedGoogle Scholar
  • 24 Pohl A L. Multiple testing with cancer markers. In: Sell S (Hrsg) Serological Cancer Markers. Totowa; Humana Press 1992: 473-494
    Google Scholar
  • 25 Schäfer B W, Wicki R, Engelkamp D, Mattei M G, Heizman C W. Isolation of a YAC clone covering a cluster of nine S 100 genes on human chromosome 1 q 21: Rationale for a new nomenclature of S 100 calcium-binding protein family.  Genomics. 1995;  25 638-643
    CrossrefPubMedGoogle Scholar
  • 26 Schmitz C, Brenner W, Henze E, Christophers E, Hauschild A. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.  Anticancer Res. 2000;  20 5059-5063
    PubMedGoogle Scholar
  • 27 von Schoultz E, Hansson L O, Djureen E, Hansson J, Kärnell R, Nilsson B, Stigbrand T, Ringborg U. Prognostic value of serum analyses of S-100β protein in malignant melanoma.  Melanoma Res. 1996;  6 133-137
    PubMedGoogle Scholar
  • 28 Stahlecker J, Gauger A, Bosserhoff A, Büttner R, Ring J, Hein R. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.  Anticancer Res. 2000;  20 5041-5044
    PubMedGoogle Scholar
  • 29 Ugurel S, Pföhler C, Tilgen W, Reinhold U. S100B serum protein - a new marker in the diagnosis and monitoring of Langerhans cell histiocytosis.  Br J Dermatol. 2000;  143 198-233
    CrossrefPubMedGoogle Scholar
  • 30 De Vries T J, Fourkour A, Punt C J, Diepstra H, Ruiter D J, van Muijen G N. Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood.  Br J Cancer. 1999;  81 1066-1070
    CrossrefPubMedGoogle Scholar

Priv.-Doz. Dr. A. Hauschild

Universitäts-Hautklinik Kiel

Schittenhelmstraße 7 · 24105 Kiel ·

Email: ahauschild@dermatology.uni-kiel.de

      >